Fisher & Paykel Healthcare Corporation Limited

NZSE:FPH.NZ

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🔬 Clinical Trials

🏥 Hospitals & Clinics

💻 Telehealth

Location

New Zealand

Market Cap

USD 12.82 B

Share Price

USD 21.87

Avg Daily Volume

596,150

Change (1 day)

-1.54%

Change (1 year)

15.14%

Change (YTD)

1.82%

Fisher & Paykel Healthcare Corporation Limited Shares (Diluted, Weighted) for the year ending March 31, 2025: 590,297,000

Fisher & Paykel Healthcare Corporation Limited Shares (Diluted, Weighted) is 590,297,000 for the year ending March 31, 2025, a 0.70% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Fisher & Paykel Healthcare Corporation Limited Shares (Diluted, Weighted) for the year ending March 31, 2024 was 586,178,934, a 0.78% change year over year.
Fisher & Paykel Healthcare Corporation Limited Shares (Diluted, Weighted) for the year ending March 31, 2023 was 581,630,919, a 0.28% change year over year.
Fisher & Paykel Healthcare Corporation Limited Shares (Diluted, Weighted) for the year ending March 31, 2022 was 579,992,621, a 0.16% change year over year.
Fisher & Paykel Healthcare Corporation Limited Shares (Diluted, Weighted) for the year ending March 31, 2021 was 579,049,643, a 0.00% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses	Revenue

NZSE: FPH.NZ

Fisher & Paykel Healthcare Corporation Limited

CEO	Mr. Lewis G. Gradon
IPO Date	Jan. 1, 2000
Location	New Zealand
Headquarters	15 Maurice Paykel Place
Employees	6,978
Sector	🏥 Health Care
Industries Medical Instruments 🔬 Clinical Trials 🏥 Hospitals & Clinics 💻 Telehealth

Description

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system. In addition, it provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.